NCT07393490Recruiting
Effect of Apneic Oxygenation of the Non-ventilated Lung During Lung Cancer Surgery.
The Effect of Apneic Oxygenation of the Non-ventilated Lung on the Expression of Hypoxia-inducible Factor-1 Alpha (HIF-1α) and Interleukin-6 (IL-6) in Lung Tissue During Lung Cancer Surgery.
Source: ClinicalTrials.gov · Last updated 26 Jun 2026
Brief summary (registry, in English)
This study investigates the effect of apneic oxygenation of the non-ventilated lung on local and systemic inflammatory response during lung cancer surgery. Patients undergoing surgical resection of lung cancer often require one-lung ventilation during anaesthesia. This results in alveolar hypoxia accompanied by upregulated expression of inflammatory markers. Apneic oxygenation of the non-ventiladed lung may influence inflammatory processes and oxygenation during surgery. The aim of this study is to evaluate whether apneic oxygenation affects inflammatory markers in lung tissue and postoperative recovery in patients undergoing lung cancer surgery. The study is conducted at a single center and includes adult patients scheduled for elective lung cancer surgery. Data will be collected durig the perioperative period. The results of this study may contribute to improved anaesthetic management and patient outcomes during thoracic surgery.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- First submitted
- 23 Jan 2026
- Start date
- 2 Jan 2025
- Primary completion date
- Aug 2026
- Lead sponsor
- Osijek University Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07393490
What you commit to
- Study type: Interventional
- Planned participants: 56
- From 2 Jan 2025 to the primary completion date, Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Chronic corticosteroid therapy and/or other immunomodulatory treatments
- Surgical procedure expected to last less than 2 hours
Other illness
- Severe pulmonary diseases, including:
- Chronic obstructive pulmonary disease classified as GOLD stage 3-4 (Global Initiative for Chronic Obstructive Lung Disease).
- Severe asthma according to GINA classification (Global Initiative for Asthma), step 4.
- Severe interstitial lung disease defined by: Forced vital capacity (FVC) \< 50% predicted, diffusing capacity of the lung for carbon monoxide (DLCO) \< 40% predicted, presence of extensive pulmonary fibrosis on computed tomography (CT)
- New-onset intraoperative cardiac arrhythmias
Age
- Age younger than 18 years
Other
- Intraoperative hemodynamic instability, defined as: Mean arterial pressure \< 60 mmHg for more than 30 minutes despite adequate volume resuscitation, requirement for high-dose vasopressor support (norepinephrine \> 0.2 µg/kg/min)
- Significant intraoperative blood loss, defined as the need for transfusion of more than two units of packed red blood cells
- Intraoperative ventilatory instability, defined as: Severe hypoxemia (PaO₂ \< 60 mmHg or SpO₂ \< 85% with FiO₂ 1.0), hypercapnia (PaCO₂ \> 70 mmHg with pH \< 7.2), inability to achieve adequate ventilation.
Who the study is looking for
- Adults aged 18 years or older
- Patients scheduled to undergo surgical resection of a single lung segment for lung cancer
- Written informed consent provided
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Center Osijek Coordinator of this site? Confirm its status | Osijek | Croatia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.